already is approved for use in people ages 2 through 55 years.
provides protection against four strains of IMD (A, C, W-135 and Y) and will replace the current vaccine which guards only against the C strain.
was first licensed in January 2005, and it is indicated for use in persons aged 11 to 55 years to prevent invasive meningococcal disease caused by several Neisseria meningitis serogroups including A, C, and Y.
vaccine is the first quadrivalent conjugate meningococcal vaccine for the prevention of meningococcal disease, a serious bacterial infection that can cause meningitis and sepsis (blood infection).
Safety in Concomitant Use with Menactra
[Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine] and Adacel [Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap)]
Meningococcal vaccines: market development Meningococcal vaccines: market development - Menomune Meningococcal vaccines: market development - Menactra
Meningococcal vaccines: market development - Menveo Meningococcal vaccines: market development C All sales 2004-13 Meningococcal vaccines: market development C Sales per vaccine, 2013 Meningococcal vaccines: market development C Sales per country/region, 2013 Manufacturers and product characteristics: conjugated ACWY vaccines Manufacturers and product characteristics: unconjugated ACWY vaccines Novartis/GSK deal - portfolio synergy/overlap ACWY vaccines ACWY market segments Disease background Market segments for ACWY vaccines Adolescent markets for ACWY vaccines
vaccine is the world's first quadrivalent conjugate vaccine licensed for the prevention of meningococcal disease and is designed to offer protection against four serogroups of Neisseria meningitidis (A, C, Y, and W-135), the bacterium that causes meningococcal infection.
Take Care Clinic nurse practitioners and physician assistants can also administer appropriate immunizations for school-aged children, such as flu, Tdap (tetanus, diphtheria, pertussis), Menactra
(meningitis), Varicella (chicken pox), MMR (measles, mumps, rubella) and GARDASIL[R] (HPV).
The FDA's approval of the Menactra
booster vaccination gives health care providers the option to use a meningococcal conjugate vaccine that is approved for both primary and booster immunization, which aligns with the CDC's recommendations for preventing cases of meningococcal meningitis," said David P.
Her study used the Cervarix formulation of HPV vaccine, the Boostrix formulation of Tdap, and the Menactra
formulation of meningococcal vaccine.
Vaccine is Safe and Effective in Preventing Potentially Deadly Meningococcal Disease
The global meningococcal vaccines market is segmented as follow: Meningococcal Vaccines Market, by Type Polysaccharide Vaccines, by Brand Menomune Mencevax NmVac4 Others Quadri Meningo Bi Meningo Conjugate Vaccines, by Brand Menactra
The key products, such as Menactra
, ActHIB, Merrem, AmBisome, the Menjugate vaccine and Meningitec vaccine, are able to satisfy the demands of treated patients.
Currently, tetravalent conjugate vaccines, such as Sanofi's Menactra
and Novartis' Menveo, account for the vast majority of global sales, with the US adolescent market being the key target segment.
As of October 2007, VAERS has received 24 reports of Guillain-Barre syndrome following use of the tetravalent meningo-coccal conjugate vaccine (MCV4), marketed as Menactra
by Sanofi Pasteur.